RU2006126078A - Детектирование cd20 в терапии аутоиммунных заболеваний - Google Patents

Детектирование cd20 в терапии аутоиммунных заболеваний Download PDF

Info

Publication number
RU2006126078A
RU2006126078A RU2006126078/13A RU2006126078A RU2006126078A RU 2006126078 A RU2006126078 A RU 2006126078A RU 2006126078/13 A RU2006126078/13 A RU 2006126078/13A RU 2006126078 A RU2006126078 A RU 2006126078A RU 2006126078 A RU2006126078 A RU 2006126078A
Authority
RU
Russia
Prior art keywords
sample
patient
antibody
autoimmune disease
detected
Prior art date
Application number
RU2006126078/13A
Other languages
English (en)
Inventor
Пол Дж. БРУНЕТТА (US)
Пол Дж. БРУНЕТТА
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2006126078A publication Critical patent/RU2006126078A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Claims (19)

1. Способ лечения аутоиммунного заболевания у пациента, включающий в себя
(a) детектирование CD20 в образце, полученном из огранизма пациента; и
(b) если в образце детектируется CD20, введение CD20-антагониста пациенту в количестве, эффективном для лечения аутоиммунного заболевания.
2. Способ по п.1, согласно которому антагонист содержит антитело.
3. Способ по п.2, согласно которому антитело не конъюгировано с цитотоксическим агентом.
4. Способ по п.2, согласно которому антитело содержит ритуксимаб.
5. Способ по п.2, согласно которому антитело содержит гуманизированное [антитело] 2H7.
6. Способ по п.2, согласно которому антитело конъюгировано с цитотоксическим агентом.
7. Способ по п.1, согласно которому пациент страдает ревматоидным артритом.
8. Способ по п.7, согласно которому образец получен при биопсии [тканиU синовиума или синовиальной жидкости.
9. Способ по п.1, согласно которому пациент страдает волчанкой.
10. Способ по п.9, согласно которому образец представляет собой образец биопсии лимфатического узла, биопсии костного мозга или мононуклеарные клетки периферической крови (PBMC).
11. Способ по п.1, согласно которому пациент страдает язвенным колитом или воспалительным заболеванием кишечника (IBD).
12. Способ по п.11, согласно которому образцом является образец, полученный при эндоскопии.
13. Способ по п.1, согласно которому пациент страдает дерматологическим заболеванием или имеет дерматологическое проявление аутоиммунного заболевания.
14. Способ по п.13, согласно которому заболевание выбрано из группы, состоящей из псориаза, обыкновенной пузырчатки, ревматоидного артрита, волчанки и васкулита.
15. Способ по п.13, согласно которому образец представляет собой образец трепанобиопсии, мононуклеарные клетки периферической крови (PBMC) или образец [ткани] лимфатического узла.
16. Способ по п.1, который, по существу, состоит во введении антагониста млекопитающему.
17. Способ по п.1, согласно которому белок CD20 детектируют на стадии (a).
18. Способ по п.1, согласно которому нуклеиновую кислоту CD20 детектируют на стадии (a).
19. Способ лечения аутоиммунного заболевания у пациента, включающий в себя
(a) детектирование CD20-положительных В-клеток в образце, полученном из огранизма пациента; и
(b) если в образце детектируются CD20-положительные В-клетки, введение CD20-антитела пациенту в количестве, эффективном для лечения аутоиммунного заболевания.
RU2006126078/13A 2003-12-19 2004-12-07 Детектирование cd20 в терапии аутоиммунных заболеваний RU2006126078A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53136303P 2003-12-19 2003-12-19
US60/531,363 2003-12-19

Publications (1)

Publication Number Publication Date
RU2006126078A true RU2006126078A (ru) 2008-01-27

Family

ID=34710220

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006126078/13A RU2006126078A (ru) 2003-12-19 2004-12-07 Детектирование cd20 в терапии аутоиммунных заболеваний

Country Status (11)

Country Link
US (1) US20050186206A1 (ru)
EP (1) EP1696955A2 (ru)
JP (1) JP2007514787A (ru)
KR (2) KR20090036154A (ru)
CN (1) CN1917901A (ru)
AU (2) AU2004305560A1 (ru)
BR (1) BRPI0417105A (ru)
CA (1) CA2549122A1 (ru)
MX (1) MXPA06006864A (ru)
RU (1) RU2006126078A (ru)
WO (1) WO2005060999A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
PL1692182T3 (pl) 2003-11-05 2010-09-30 Roche Glycart Ag Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5828151B6 (ja) 2009-01-06 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アテローム性動脈硬化の処置のためのｂ細胞枯渇剤
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
PT752248E (pt) * 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
BR9913645A (pt) * 1998-08-11 2001-09-25 Idec Pharma Corp Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
EP1637160A3 (en) * 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
PT1194167E (pt) * 1999-06-09 2009-10-23 Immunomedics Inc Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
CA2405632A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DE60139689D1 (de) * 2000-06-22 2009-10-08 Univ Iowa Res Found Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
ES2364816T3 (es) * 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
US7405047B2 (en) * 2001-06-25 2008-07-29 Phadia Ab Method for estimation of the amount of specific cell types
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
HUP0600342A3 (en) * 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
JP4498746B2 (ja) * 2002-02-14 2010-07-07 イミューノメディクス、インコーポレイテッド 抗ｃｄ２０抗体およびその融合タンパク質ならびに使用法
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy

Also Published As

Publication number Publication date
WO2005060999A2 (en) 2005-07-07
KR20060109494A (ko) 2006-10-20
WO2005060999A3 (en) 2006-01-26
CA2549122A1 (en) 2005-07-07
BRPI0417105A (pt) 2007-02-06
US20050186206A1 (en) 2005-08-25
EP1696955A2 (en) 2006-09-06
WO2005060999A9 (en) 2008-09-25
AU2004305560A1 (en) 2005-07-07
AU2009201932A1 (en) 2009-06-04
JP2007514787A (ja) 2007-06-07
MXPA06006864A (es) 2006-08-23
CN1917901A (zh) 2007-02-21
KR20090036154A (ko) 2009-04-13

Similar Documents

Publication Publication Date Title
RU2006126078A (ru) Детектирование cd20 в терапии аутоиммунных заболеваний
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
Dubash et al. Ultrasound imaging in psoriatic arthritis: what have we learnt in the last five years?
JP4662891B2 (ja) 採便容器
CA3189109A1 (en) Methods and systems for cell-free dna fragment size densities to assess cancer
Norenberg et al. Corynebacterium pyogenes septic arthritis with plasma cell synovial infiltrate and monoclonal gammopathy
CN112661841A (zh) 一种中和新冠病毒新表位的全人单克隆抗体17-2及其应用
Girard et al. Subcutaneous phaeohyphomycosis due to Pyrenochaeta romeroi in a patient with leprosy
Larsson et al. Localization of various plasma proteins in the skin in rheumatoid arthritis: an immunofluorescent microscopic study of skin biopsies
Mahmood et al. Psoriatic arthritis: A review
Makhlouf et al. Serum angiopoietin-2 as a noninvasive diagnostic marker of stages of liver fibrosis in chronic hepatitis C patients
CN103255226A (zh) 旋毛虫pcr-dhplc检测引物、试剂盒及检测方法
Zhao et al. IDDF2023-ABS-0211 Highly immunoglobulin a/g/m-coated gut microbial consortia in inflammatory bowel disease
Wang et al. AB0158 The Expression of Blimp-1 in B Cells in Peripheral Blood from Patients with SLE and Its Clinical Significance
Cao et al. 29P Targeting CXCR4 promotes antitumor immunity through TOX-mediated CD8+ T cell activation
Allaberdiev et al. MORPHOMETRIC FEATURES OF MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS WITH NEPHROTIC SYNDROME AND CORRELATION OF MORPHO-LABORATORY PARAMETERS
Permin et al. Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin
Qiu IDDF2023-ABS-0193 Characteristics of small bowel lesions in crohn’s disease detected by capsule endoscopy
Mori et al. Lymph Node Infarction in Classical Hodgkin's Lymphoma
CN114113601A (zh) 尿液肝素辅因子ii及其多肽片段在烧伤中的应用
Ishii et al. Reactive arthritis due to asymptomatic infection of Chlamydia trachomatis
Borel et al. Comparison of a digestion-sedimentation technique with the Kato-Katz technique in the detection and quantification of S. mansoni eggs in light to moderate infections
CA2251058A1 (en) Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone h1
CN113777302A (zh) 尿液补体因子d及其多肽片段在烧伤中的应用
Cavallo Pathologic approach to the diagnosis of vasculitis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20080610

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20090515

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100128